Protective action of NDP-MSH in experimental subarachnoid hemorrhage.
Gatti. Stefano S; Lonati. Caterina C; Acerbi. Francesco F; Sordi. Andrea A; Leonardi. Patrizia P; Carlin. Andrea A; Gaini. Sergio M SM; Catania. Anna A
Key Findings
- A tiny dose (10 ng) of NDP‑MSH given directly to the spinal fluid caused a protective, pre‑conditioning effect on brain arteries.
- Systemic injection (100 µg IV) after induced subarachnoid hemorrhage prevented most of the harmful gene expression changes seen 4 hours later.
- Treatment reduced activation of ERK1/2 and IκBα signaling pathways and significantly lessened arterial vasospasm five days after injury.
Practical Outcomes
- While the study shows that NDP‑MSH can be neuroprotective in a rat model of brain bleed, it is still early‑stage animal research. For biohackers, the data suggest melanocortin peptides might have anti‑inflammatory and vascular benefits, but no safe human dosing or protocol exists yet. More clinical work is needed before anyone should try this peptide for brain health or stroke prevention.
Summary
In rats, a synthetic version of the hormone alpha‑MSH called NDP‑MSH helped protect brain blood vessels after a simulated bleed in the space around the brain. The peptide reduced harmful gene activity, lowered stress‑related protein signals, and lessened the narrowing of arteries that usually follows such bleeding.
Abstract
Subarachnoid hemorrhage (SAH) is still a major cause of morbidity and mortality. α-Melanocyte stimulating hormone (α-MSH) and other melanocortin peptides exert potent neuroprotective action and they might modulate key molecules involved in SAH-induced vasospasm. The aim of this research was to determine whether treatment with the α-MSH analog Nle4,DPhe7-α-MSH (NDP-MSH) exerts protective effects in experimental SAH in the rat. Initial experiments examined effects of NDP-MSH on the basilar artery phenotype in the absence of injury. In these tests intrathecal injection of small concentrations (10ng) of the peptide induced a tolerant phenotype similar to that observed after ischemic preconditioning. Then the effect of systemic treatment with NDP-MSH (100μg i.v.) on experimental SAH was evaluated. SAH was induced by a single-blood injection into the cisterna magna. The basilar artery phenotype was examined at 4h and the artery caliber at 5days following SAH. Expression of 96 genes was analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR) using Custom Taqman Low-Density Arrays. Four hours after SAH, the transcriptional profile of the basilar artery was deeply disrupted. Transcript alteration included genes involved in inflammation, stress response, apoptosis, and vascular remodeling. Treatment with NDP-MSH prevented most of these transcription changes and decreased phosphorylation of extracellular-signal-regulated kinases (ERK1/2) and inhibitor protein IκBα. Vasospasm on day 5 was significantly reduced by NDP-MSH administration. These results combine with others on CNS inflammation to suggest that the melanocortins could be safe and effective therapeutic candidates to treat SAH-related complications.
Study Information
pubmed
2012
2012-01-02T00:00:00.000Z
10.1016/j.expneurol.2011.12.039
26
59